Eli Lilly (NYSE:LLY) is the most valuable healthcare company, with Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) rounding out the top three. Pharmaceutical companies dominate this market sector, comprising over half of the largest healthcare companies by market cap.
The 10 largest
Largest companies by market cap in the healthcare sector
(Editor's note: Rankings are as of Sept. 2, 2025.)
| Name and ticker | Market cap | Current price | Industry |
|---|---|---|---|
| Eli Lilly (NYSE:LLY) | $722 billion | $801.50 | Pharmaceuticals |
| Johnson & Johnson (NYSE:JNJ) | $447 billion | $184.93 | Pharmaceuticals |
| AbbVie (NYSE:ABBV) | $409 billion | $239.64 | Biotechnology |
| UnitedHealth Group (NYSE:UNH) | $313 billion | $346.12 | Healthcare Providers and Services |
| AstraZeneca Plc (NASDAQ:AZN) | $238 billion | $82.61 | Pharmaceuticals |
| Novartis (NYSE:NVS) | $243 billion | $130.09 | Pharmaceuticals |
| Abbott Laboratories (NYSE:ABT) | $233 billion | $130.53 | Healthcare Equipment and Supplies |
| Merck (NYSE:MRK) | $210 billion | $87.77 | Pharmaceuticals |
| Novo Nordisk (NYSE:NVO) | $187 billion | $57.41 | Pharmaceuticals |
| Thermo Fisher Scientific (NYSE:TMO) | $183 billion | $512.38 | Life Sciences Tools and Services |
Companies 1 - 3
1. Eli Lilly
- Market cap: $695.83 billion (as of Sept. 2)
- Revenue (TTM): $53.3 billion
- Gross profit (TTM): $44.0 billion
- Five-year annualized return: 39.15%
- Year founded: 1876
Pharmaceutical giant Eli Lilly is the world's most valuable drug company. A chemist and veteran of the Union Army founded the company in 1876, and it later became the first to mass-produce insulin and the polio vaccine.
Some of its top products are diabetes medications, weight loss drugs, obesity treatments, and antidepressants such as Prozac. In 2024, Eli Lilly partnered with Amazon (NASDAQ:AMZN) to offer home delivery of select medications.
2. Johnson & Johnson
- Market cap: $428.83 billion (as of Sept. 2)
- Revenue (TTM): $90.6 billion
- Gross profit (TTM): $61.6 billion
- Five-year annualized return: 6.55%
- Year founded: 1886
Johnson & Johnson is a pharmaceutical and medical device company. Its two primary business segments are Innovative Medicine, which develops and markets prescription drugs, and MedTech, which manufactures medical devices, including Acuvue contact lenses.
Until 2023, Johnson & Johnson also had a robust consumer healthcare division that produced Tylenol, Band-Aid, and many other household names. It spun off that division into a new business, Kenvue (NYSE:KVUE).
3. AbbVie
- Market cap: $374.37 billion (as of Sept. 2)
- Revenue (TTM): $58.3 billion
- Gross profit (TTM): $41.4 billion
- Five-year annualized return: 23.05%
- Year founded: 2012
AbbVie is a biotechnology company that develops treatments for serious diseases. It has produced therapies for illnesses, including autoimmune diseases, plaque psoriasis, blood cancers, and advanced Parkinson's disease. It also acquired Capstan Therapeutics, a cell and gene therapy company, for $2.1 billion this year.
AbbVie is a relatively new company that started as a spinoff of Abbott Laboratories. It's now one of the better dividend stocks in the healthcare sector. It has regularly raised its dividend payout, resulting in a high dividend yield.
Companies 4 - 6
4. UnitedHealth Group
- Market cap: $279.67 billion (as of Sept. 2)
- Revenue (TTM): $422.8 billion
- Gross profit (TTM): $88.1 billion
- Five-year annualized return: 1.05%
- Year founded: 1977
UnitedHealth Group provides health insurance and healthcare services. It sells health insurance products through its UnitedHealthcare division and offers healthcare services through its Optum division.
Although UnitedHealth Group is one of the largest healthcare companies, it has faced a number of high-profile issues. A subsidiary, Change Healthcare, was responsible for the largest reported healthcare data breach in history in 2024. CEO Andrew Witty abruptly resigned in May 2025 for personal reasons, and the company replaced its CFO in July. Also in July, UnitedHealth disclosed that it's facing a criminal and civil investigation by the Department of Justice.
5. AstraZeneca
- Market cap: $248.63 billion (as of Sept. 2)
- Revenue (TTM): $56.5 billion
- Gross profit (TTM): $46.0 billion
- Five-year annualized return: 10.66%
- Year founded: 1913 (Astra AB), Zeneca (1993), 1999 (merger of Astra AB and Zeneca)
AstraZeneca is a multinational biotech company formed through the 1999 merger of Astra, a Swiss company, and Zeneca, a British company. Its headquarters are in Cambridge, England.
This company manufactures prescription medications for many major diseases, including cardiovascular disease, metabolic disorders, renal disease, and rare diseases. It has 11 research and development (R&D) centers, 28 manufacturing sites, and a market presence in more than 130 countries.
6. Novartis
- Market cap: $240.31 billion (as of Sept. 2)
- Revenue (TTM): $55.2 billion
- Gross profit (TTM): $42.1 billion
- Five-year annualized return: 13.28%
- Year founded: 1886 (Sandoz), 1970 (Ciba-Geigy), 1996 (merger of Ciba-Geigy and Sandoz)
Novartis is a Swiss pharmaceutical company. It manufactures prescription drugs for various diseases. Some of its bestselling products include Entresto, a medication used to treat heart failure; Cosentyx, a treatment for psoriasis; and Kesimpta, a treatment for certain forms of multiple sclerosis (MS).
This Swiss company is also incorporating artificial intelligence (AI) technology into its business. Novartis is partnering with Viz.ai to provide AI-powered care for cancer patients.
Companies 7 - 10
7. Abbott Laboratories
- Market cap: $228.80 billion (as of Sept. 2)
- Revenue (TTM): $43.1 billion
- Gross profit (TTM): $24.1 billion
- Five-year annualized return: 6.37%
- Year founded: 1888
Abbott Laboratories manufactures healthcare products and medical equipment. It has four main business segments: established pharmaceutical products, diagnostic products, nutritional products, and medical devices.
Like its spinoff AbbVie, Abbott Laboratories is popular among dividend investors. It has raised its dividend for more than 50 consecutive years, putting it on the list of Dividend Kings.
8. Merck
- Market cap: $213.51 billion (as of Sept. 2)
- Revenue (TTM): $63.6 billion
- Gross profit (TTM): $48.7 billion
- Five-year annualized return: 4.14%
- Year founded: 1891
Merck is a pharmaceutical company known for its impressive oncology portfolio. That includes its leading drug, Keytruda, which is also the bestselling drug worldwide. Merck also makes diabetes medications, an HPV vaccine, and a chickenpox vaccine.
This company has made several major acquisitions recently. In 2024 alone, it acquired Harpoon Therapeutics, Abceutics, EyeBio, and Modifi Biosciences. In 2025, it acquired SpringWorks Therapeutics for $3.4 billion. However, it's now aiming to save $3 billion in costs by 2027 and plans to cut 6,000 jobs, getting rid of about 8% of its workforce.
9. Novo Nordisk
- Market cap: $189.78 billion (as of Sept. 2)
- Revenue (TTM): $48.7 billion*
- Gross profit (TTM): $40.9 billion*
- Five-year annualized return: 13.54%
- Year founded: 1923
*Converted from Danish krone.
Based in Denmark, Novo Nordisk is a leading pharmaceutical company that develops medications for diabetes, weight loss, and rare diseases. It's the maker of Ozempic, a treatment for diabetes, and Wegovy, a weight loss drug.
Novo Nordisk has a market presence in 170 countries. It's one of the biggest companies in Europe, and at one point, its market cap surpassed Denmark's gross domestic product (GDP).
10. Thermo Fisher Scientific
- Market cap: $184.10 billion (as of Sept. 2)
- Revenue (TTM): $43.2 billion
- Gross profit (TTM): $17.8 billion
- Five-year annualized return: 3.30%
- Year founded: 1902 (Fisher Scientific), 1956 (Thermo Electron), 2006 (merged into Thermo Fisher Scientific)
Thermo Fisher Scientific is a life science and research company. It has a large, diverse portfolio of products that includes analytical equipment, diagnostic kits and instruments, and life science products used in medical research and diagnostics.
This Massachusetts-based company has a global presence with operations around the world. It also employs approximately 125,000 people. In September 2025, Thermo Fisher added to its Life Sciences Solutions segment when it acquired the purification and filtration business of Solventum (NYSE:SOLV) for $4 billion.
Related investing topics
Takeaways
Healthcare sector takeaways for investors
Investing in healthcare stocks can be challenging. Among the 10 largest healthcare companies, only four have outperformed the S&P 500 over the last five years.
The sector also has some unique risks. The development of new products often requires a lengthy regulatory process, particularly for pharmaceutical companies. And if a company's product may have caused harm to a consumer, there's the possibility of a lawsuit.
Like most businesses, healthcare companies have been affected by the Trump administration's import tariffs. Tariffs could increase the cost of medical devices and lead to pharmaceutical shortages, if they stand -- a federal court ruled that the tariffs are illegal, but the Trump administration has appealed the ruling. Regardless, Eli Lilly, Johnson & Johnson, and AstraZeneca are all investing heavily to expand their U.S. manufacturing to help reduce the potential impact of tariffs.
Even with those risks, there are also plenty of reasons why healthcare is an attractive sector for investors. Some of the top healthcare companies pay high dividends, which is great for those looking to build passive income. Healthcare stocks also tend to be resistant to market downturns. After all, no matter how the economy is doing, people always need healthcare.
